2025 · Abstract/Manuscript · GSK
Health System Partner
Resources and insights tagged health system partner from Headwater.
Publications
37
Total Publications
18
Abstract/Manuscript
17
Oral Presentation
2
Poster Presentation
2024 · Abstract/Manuscript
Staging and clean room: Constructs designed to facilitate transparency and reduce bias in comparative analyses of real-world data
Read more →2024 · Abstract/Manuscript · University of North Carolina at Chapel Hill
Propensity Score Methods for Confounding Control in Observational Studies of Therapeutics for COVID-19 Infection
Read more →2024 · Poster Presentation · University of North Carolina at Chapel Hill · Methods/Pharmacoepi
Addressing RWE Challenges in Real-Time: The 'Clean Room Committee' Approach
Read more →2024 · Abstract/Manuscript · University of North Carolina at Chapel Hill
STI prevalence, partner notification and HIV risk perception in a cohort of women completing STI screening as part of a safer conception study.
Read more →2024 · Abstract/Manuscript · University of North Carolina at Chapel Hill
Preexposure prophylaxis uptake, adherence, and persistence during periconception periods among women in South Africa.
Read more →2024 · Abstract/Manuscript · Botswana Harvard AIDS Institute Partnership
Designing an implementation science clinical trial to integrate hypertension and cardiovascular diseases care into existing HIV services package in Botswana (InterCARE).
Read more →2024 · Abstract/Manuscript · Botswana Harvard AIDS Institute Partnership
Predictors of HIV seroconversion in Botswana: machine learning analysis in a representative, population-based HIV incidence cohort.
Read more →2024 · Abstract/Manuscript · University of North Carolina at Chapel Hill
Uptake and Persistence of Safer Conception Strategies Among South African Women Planning for Pregnancy.
Read more →2024 · Abstract/Manuscript · Botswana Harvard AIDS Institute Partnership
Quantitative outcomes of a type 2 single arm hybrid effectiveness implementation pilot study for hypertension-HIV integration in Botswana.
Read more →2023 · Abstract/Manuscript · University of North Carolina at Chapel Hill
Pragmatic considerations for negative control outcome studies to guide non-randomized comparative analyses: A narrative review
Read more →2023 · Abstract/Manuscript · University of North Carolina at Chapel Hill
Controlling for Differential Regression-To-The-Mean via Propensity Scores: A Simulation Study
Read more →2023 · Abstract/Manuscript · Botswana Harvard AIDS Institute Partnership
Population-level viremia predicts HIV incidence at the community level across the Universal Testing and Treatment Trials in eastern and southern Africa.
Read more →2023 · Oral Presentation · Botswana Harvard AIDS Institute Partnership · Methods/Pharmacoepi
Methods and New Approaches in Pragmatic Trials Case Study: Botswana Combination Prevention Project
Read more →2022 · Abstract/Manuscript · University of North Carolina at Chapel Hill
Lipid Testing Trends Before and After Hospitalization for Myocardial Infarction Among Adults in the United States, 2008-2019
Read more →2022 · Abstract/Manuscript · University of North Carolina at Chapel Hill
DAG With Omitted Objects Displayed (DAGWOOD): a framework for revealing causal assumptions in DAGs
Read more →2022 · Oral Presentation · University of North Carolina at Chapel Hill · Methods/Pharmacoepi
Fusion Designs for Indirect Treatment Effects
Read more →2022 · Oral Presentation · University of North Carolina at Chapel Hill · Methods/Pharmacoepi
On Teaching Advanced Epidemiologic Methods
Read more →2022 · Oral Presentation · University of North Carolina at Chapel Hill · Methods/Pharmacoepi
Bridged treatment comparisons: an illustrative application in HIV treatment
Read more →2022 · Abstract/Manuscript · Botswana Harvard AIDS Institute Partnership
Epidemiological and viral characteristics of undiagnosed HIV infections in Botswana
Read more →2022 · Abstract/Manuscript · Botswana Harvard AIDS Institute Partnership
Achieving the UNAIDS 90-90-90 targets: a comparative analysis of four large community randomised trials delivering universal testing and treatment to reduce HIV transmission in sub-Saharan Africa.
Read more →2022 · Poster Presentation · University of North Carolina at Chapel Hill · Methods/Pharmacoepi
Oral PrEP Use Among South African Women with Plans for Pregnancy.
Read more →2021 · Abstract/Manuscript · University of North Carolina at Chapel Hill
Use of negative control outcomes to assess the comparability of patients initiating lipid-lowering therapies
Read more →2021 · Oral Presentation · University of California Los Angeles · Methods/Pharmacoepi
Fusion designs and estimators for treatment effects
Read more →2020 · Abstract/Manuscript · University of North Carolina at Chapel Hill
Who are we missing? Underrepresentation of data sources used for pharmacoepidemiology research in the United States
Read more →2020 · Oral Presentation · No · Methods/Pharmacoepi
Real world treatment patterns following the initiation of proprotein convertase subtilisin/kexin type 9 antibody inhibitors among adults in the United States, 2015-2019
Read more →2020 · Oral Presentation · No · Methods/Pharmacoepi
History of lipid lowering therapy use among adults initiating treatment with proprotein convertase subtilisin/kexin type 9 antibody inhibitors in the United States, 2015-2019
Read more →2020 · Oral Presentation · University of North Carolina at Chapel Hill · Methods/Pharmacoepi
Estimating the Effect of Depression on HIV Transmission Risk Behaviors Among People Who Inject Drugs in Vietnam: A Causal Approach
Read more →2020 · Oral Presentation · University of North Carolina at Chapel Hill · Methods/Pharmacoepi
G-computation for policy-relevant effects of interventions on time-to-event outcomes
Read more →2019 · Oral Presentation · University of North Carolina at Chapel Hill · Methods/Pharmacoepi
Using Instrumental Variables to Address Bias from Unobserved Confounders
Read more →2019 · Oral Presentation · University of North Carolina at Chapel Hill · Methods/Pharmacoepi
Commentary: Compositional data call for complex interventions
Read more →2019 · Oral Presentation · University of North Carolina at Chapel Hill · Methods/Pharmacoepi
Using Bounds to Compare the Strength of Exchangeability Assumptions for Internal and External Validity
Read more →2019 · Oral Presentation · University of North Carolina at Chapel Hill · Methods/Pharmacoepi
Informative censoring by health plan disenrollment among commercially insured adults
Read more →2019 · Oral Presentation · University of North Carolina at Chapel Hill · Methods/Pharmacoepi
Nonparametric Bounds for the Risk Function
Read more →2018 · Oral Presentation · University of North Carolina at Chapel Hill · Methods/Pharmacoepi
Agreement between electronic health records and administrative claims data for patients with multiple myeloma
Read more →2018 · Oral Presentation · University of North Carolina at Chapel Hill · Methods/Pharmacoepi
A Practical Example Demonstrating the Utility of Single-world Intervention Graphs
Read more →2018 · Oral Presentation · University of North Carolina at Chapel Hill · Methods/Pharmacoepi
Using Negative Control Outcomes to Assess the Comparability of Osteoporosis Treatment Groups
Read more →Latest News
Contact us
By submitting this form, you consent to your information used by Headwater Science for the purpose of contacting you to better understand your potential interest in Headwater Science and/or its services. For more information, see our privacy policy.
Pedestal Health projects leverage Headwater Science methods, technology and causal inference expertise where the analytical complexity is highest, comparative effectiveness studies that require dynamic treatment design, regulatory-grade external control work, methodological consultation on submission packages, and the kinds of bias-protection frameworks that consequential evidence increasingly requires.
Pedestal Health projects leverage Headwater Science methods, technology and causal inference expertise where the analytical complexity is highest, comparative effectiveness studies that require dynamic treatment design, regulatory-grade external control work, methodological consultation on submission packages, and the kinds of bias-protection frameworks that consequential evidence increasingly requires.